CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia

Proteins created from recurrent fusion genes like CBFB-MYH11 are prevalent in acute myeloid leukemia (AML), often necessary for leukemogenesis, persistent throughout the disease course, and highly leukemia specific, making them attractive neoantigen targets for immunotherapy. A nonameric peptide der...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Invest
Huvudupphovsmän: Biernacki, Melinda A., Foster, Kimberly A., Woodward, Kyle B., Coon, Michael E., Cummings, Carrie, Cunningham, Tanya M., Dossa, Robson G., Brault, Michelle, Stokke, Jamie, Olsen, Tayla M., Gardner, Kelda, Estey, Elihu, Meshinchi, Soheil, Rongvaux, Anthony, Bleakley, Marie
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society for Clinical Investigation 2020
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7524498/
https://ncbi.nlm.nih.gov/pubmed/32831296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI137723
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk